Cargando…

A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study

BACKGROUND AND OBJECTIVES: The variable CAG repeat expansion in the huntingtin gene and its inverse relationship to motor dysfunction onset are fundamental features of Huntington disease (HD). However, the wider phenotype (including non-motor features) at particular CAG lengths, ages, and functional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langbehn, Douglas R., Sathe, Swati S., Loy, Clement, Sampaio, Cristina, Mccusker, Elizabeth A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684052/ https://www.ncbi.nlm.nih.gov/pubmed/38035176 http://dx.doi.org/10.1212/NXG.0000000000200111

Ejemplares similares

Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease
por: Sathe, Swati, et al.
Publicado: (2021)

The Many Facets of Unawareness in Huntington Disease
por: McCusker, Elizabeth, et al.
Publicado: (2014)

The Clinical Picture of Psychosis in Manifest Huntington's Disease: A Comprehensive Analysis of the Enroll-HD Database
por: Rocha, Natalia P., et al.
Publicado: (2018)

Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll‐HD Study
por: Ogilvie, Amy C., et al.
Publicado: (2023)

Prevalence of neurocognitive disorder in Huntington’s disease using the Enroll-HD dataset
por: Sierra, Luis A., et al.
Publicado: (2023)

Is a Motor Criterion Essential for the Diagnosis of Clinical Huntington Disease?
por: Loy, Clement T, et al.
Publicado: (2013)

Exploring the predictors of financial impairment in Huntington’s disease using the Enroll-HD dataset
por: Harris, Kate L., et al.
Publicado: (2022)

Huntington Disease: The Complexities of Making and Disclosing a Clinical Diagnosis After Premanifest Genetic Testing
por: McCusker, Elizabeth A., et al.
Publicado: (2017)

What do we know about Late Onset Huntington’s Disease?
por: Chaganti, Sai S., et al.
Publicado: (2017)

Refining the diagnosis of Huntington disease: the PREDICT-HD study
por: Biglan, Kevin M., et al.
Publicado: (2013)

Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD)
por: Harris, Kate L, et al.
Publicado: (2020)

Machine learning in Huntington’s disease: exploring the Enroll-HD dataset for prognosis and driving capability prediction
por: Ouwerkerk, Jasper, et al.
Publicado: (2023)

Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach
por: Ko, Jinnie, et al.
Publicado: (2023)

Detection of Huntington’s disease decades before diagnosis: the Predict-HD study
por: Paulsen, J S, et al.
Publicado: (2008)

Another Perspective on Huntington’s Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD
por: Achenbach, Jannis, et al.
Publicado: (2021)

Understanding HD Psychosis: An Analysis from the ENROLL-HD Database
por: Jaini, Ashwin, et al.
Publicado: (2020)

Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington’s Disease Using the Enroll-HD Global Platform
por: Symonds, Alexander L., et al.
Publicado: (2021)

Facilitating Huntington's disease research: plasma neurofilament levels as a promising enrichment biomarker for HD-ISS stage 1
por: Sampaio, Cristina, et al.
Publicado: (2023)

Disease Burden of Huntington’s Disease (HD) on People Living with HD and Care Partners in Canada
por: Shaw, Eileen, et al.
Publicado: (2022)

Protocol for REducing Anti-Psychotic use in residential care-Huntington Disease (REAP-HD): a pilot cluster randomised controlled trial of a multifaceted intervention for health professionals
por: Loy, Clement T, et al.
Publicado: (2014)

Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials
por: Langbehn, Douglas R., et al.
Publicado: (2020)

Molecule of the month: miRNA and Huntington's disease (HD)
por: Shapshak, Paul
Publicado: (2013)

Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study
por: Paulsen, Jane S., et al.
Publicado: (2014)

Accuracy of automated amygdala MRI segmentation approaches in Huntington's disease in the IMAGE‐HD cohort
por: Alexander, Bonnie, et al.
Publicado: (2020)

Modeling Variability in the Progression of Huntington's Disease A Novel Modeling Approach Applied to Structural Imaging Markers from TRACK‐HD
por: Warner, JH, et al.
Publicado: (2016)

Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study
por: Klöppel, Stefan, et al.
Publicado: (2015)

Nrf2 Pathway in Huntington’s Disease (HD): What Is Its Role?
por: Tucci, Paolo, et al.
Publicado: (2022)

Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis
por: Scahill, Rachael I, et al.
Publicado: (2020)

Characterization of a Large Group of Individuals with Huntington Disease and Their Relatives Enrolled in the COHORT Study
por: Dorsey, E. Ray
Publicado: (2012)

Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial
por: Langbehn, Douglas R., et al.
Publicado: (2022)

Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT‐HD
por: Long, Jeffrey D., et al.
Publicado: (2015)

MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study
por: Reed, Eric R., et al.
Publicado: (2018)

Correction: Characterization of a Large Group of Individuals with Huntington Disease and Their Relatives Enrolled in the COHORT Study
por: Dorsey, E. Ray
Publicado: (2012)

Stem Cells for Huntington’s Disease (SC4HD): An International Consortium to Facilitate Stem Cell-Based Therapy for Huntington’s Disease
Publicado: (2021)

Decreased Striatal RGS2 Expression Is Neuroprotective in Huntington's Disease (HD) and Exemplifies a Compensatory Aspect of HD-Induced Gene Regulation
por: Seredenina, Tamara, et al.
Publicado: (2011)

Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
por: Frank, Samuel
Publicado: (2009)

Volumetric Analysis of the Hypothalamus in Huntington Disease Using 3T MRI: The IMAGE-HD Study
por: Gabery, Sanaz, et al.
Publicado: (2015)

Increased Body Weight of the BAC HD Transgenic Mouse Model of Huntington’s Disease Accounts for Some but Not All of the Observed HD-like Motor Deficits
por: Kudwa, Andrea E., et al.
Publicado: (2013)

Multi-Modal Neuroimaging in Premanifest and Early Huntington’s Disease: 18 Month Longitudinal Data from the IMAGE-HD Study
por: Domínguez D, Juan F., et al.
Publicado: (2013)

Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance
por: Keogh, Ruth, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9c50217bol7s8lkpn5ukg15sej